Catalent Pharma Solutions

CRO

Catalent, bucking Lonza M&A reports, buys out Pharmatek in all-cash deal

Apparent Lonza target Catalent has produced an about-face with its buyout of drug development and clinical manufacturing co Pharmatek for an undisclosed sum.

Ben Adams Sep 13, 2016 9:58am